



Figure S1

Supplementary Figure S1. Pathways and mechanistic exploration of enhanced antigen cross-presentation by BCL2 inhibitors. (A) KEGG mapping with the top candidates from the arrayed screening. The cnetplot depicts the connections of the top 15 genes and enriched KEGG pathways (top 10 according to enrichment factor). (B, C) De-iniDC_Cas9 stably knocked out for *Bcl2*, *Atg5*, *Atg7*, or *Bax* were treated with navitoclax (Nav) or venetoclax (Ven) at 0 (DMSO), 10, or 20 μ M, for 10 h to measure the induction of autophagy and apoptosis by immunoblot, or overnight with lower concentrations (5, 10 μ M) for the evaluation of antigen cross-presentation as indicated by the secretion of IL2 (D, E), and displayed as bar chart (mean \pm SD, n = 3). Statistical significance was calculated by means of the Student *t* test with Bonferroni correction. P-values are labelled in the figure to indicate significance of difference.